中文摘要：

在下一代的定序和生物信息学的进展开始了在人的癌症染色体揭示复杂基因风景，包括口头的有鳞的房间癌(OSCC ) 。充分代表 intra-tumoral 和 inter-tumoral 异质的老于世故的现出症状之前的潜的模型被要求理解癌症的分子的差异并且达到个性化的治疗的目标。在最后十年，导出病人的异种皮移植(PDX ) 模型从能保留他们肿瘤被显示出与另外的传统的现出症状之前的潜的模型相比是在翻译癌症研究的比较喜欢的现出症状之前的潜的工具的施主的组织学、基因的特征的人的肿瘤样品产生了。明确地，遗传上明确的 PDX 模型能被使用加速指向的 antitumor 药开发和 biomarker 发现。最近，我们成功地为翻译癌症研究作为我们的肿瘤简历银行的部分建立了并且描绘一块 OSCC PDX 面板。在这篇论文，我们讨论 PDX 模型的建立，描述，和现出症状之前的潜的应用。特别地，我们基于验证注解集中于 PDX 模型的分类和应用，包括测试信息的 clinicopathological 特征， genomic 侧面，和药理学。我们在不久的将来也为耐心的层化和治疗优化在 co 临床的试用的开发探索这块注解得好的 PDX 面板的翻译的值。尽管各种各样的限制仍然存在，这条现出症状之前的潜的途径应该进一步被测试并且改善。

英文摘要：

Advances in next-generation sequencing and bioinformatics have begun to reveal the complex genetic landscape in human cancer genomes, including oral squamous cell carcinoma （OSCC）. Sophisticated preclinical models that fully represent intra- and inter-tumoral heterogeneity are required to understand the molecular diversity of cancer and achieve the goal of personalized therapies. Patient-derived xenograft （PDX） models generated from human tumor samples that can retain the histological and genetic features of their donor tumors have been shown to be the preferred preclinical tool in translational cancer research compared with other conventional preclinical models. Specifically, genetically well-defined PDX models can be applied to accelerate targeted antitumor drug development and biomarker discovery. Recently, we have successfully established and characterized an OSCC PDX panel as part of our tumor bio-bank for translational cancer research. In this paper, we discuss the establishment, characterization, and preclinical applications of the PDX models. In particular, we focus on the classification and applications of the PDX models based on validated annotations, including clinicopathological features, genomic profiles, and pharmacological testing information. We also explore the translational value of this well-annotated PDX panel in the development of co-clinical trials for patient stratification and treatment optimization in the near future. Although various limitations still exist, this preclinical approach should be further tested and improved.